Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1 - Trial NCT06353321
Access comprehensive clinical trial information for NCT06353321 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Texas Southwestern Medical Center and is currently Not yet recruiting. The study focuses on Prostate Cancer. Target enrollment is 25 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
PET-CT imaging subsystem of the RefleXion X1 System Device
Observational
diagnostic test
Sponsor & Location
University of Texas Southwestern Medical Center
Timeline & Enrollment
N/A
Sep 01, 2024
Dec 01, 2025
Primary Outcome
Qualitative assessment of RefleXion X1 imaging performance with Illuccix PSMA PET imaging agent immediately following a standard of care Illuccix PET/CT
Summary
To qualitatively determine the imaging performance of PET-CT imaging subsystem of the
 RefleXion X1 System Device in patients undergoing standard-of-care (SOC) [68Ga]-PSMA-11
 PET-CT using Illuccix on the same day.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06353321
Non-Device Trial